Sonnet BioTherapeutics Holdings, Inc.
SONN
$1.36
-$0.01-0.73%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 673.99% | -87.42% | -67.76% | -53.27% | -49.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 673.99% | -87.42% | -67.76% | -53.27% | -49.83% |
| Cost of Revenue | 145.34% | -9.82% | -135.19% | -125.25% | -114.25% |
| Gross Profit | -111.30% | -442.26% | 135.97% | 126.04% | 115.05% |
| SG&A Expenses | 26.64% | -13.96% | -22.17% | -32.11% | -30.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.15% | -37.34% | -45.78% | -52.26% | -50.25% |
| Operating Income | 7.19% | 36.95% | 45.61% | 52.25% | 50.26% |
| Income Before Tax | 35.88% | 60.51% | 64.65% | 68.23% | 50.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.78% | 60.51% | 64.65% | 68.23% | 50.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.78% | 60.51% | 64.65% | 68.23% | 50.25% |
| EBIT | 7.19% | 36.95% | 45.61% | 52.25% | 50.26% |
| EBITDA | 7.19% | 36.97% | 45.63% | 52.28% | 50.28% |
| EPS Basic | 90.49% | 95.56% | 95.36% | 94.83% | 90.54% |
| Normalized Basic EPS | 90.56% | 95.56% | 95.36% | 94.83% | 90.54% |
| EPS Diluted | 90.41% | 95.53% | 95.34% | 94.82% | 90.54% |
| Normalized Diluted EPS | 90.53% | 95.55% | 95.35% | 94.83% | 90.54% |
| Average Basic Shares Outstanding | 336.65% | 404.60% | 484.41% | 686.44% | 740.67% |
| Average Diluted Shares Outstanding | 340.16% | 411.05% | 494.71% | 704.76% | 740.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |